Taxotere gets fast track status for head and neck cancer indication

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

Taxotere gets fast track status for head and neck cancer indication

BRIDGEWATER, New Jersey—Sanofi-aventis has received priority review from the FDA for its supplemental New Drug Application for Taxotere (docetaxel) in combination with cisplatin and fluorouracil for induction (neoadjuvant) therapy of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) prior to chemoradiotherapy and surgery. The combination is currently approved for induction therapy of inoperable advanced SCCHN. The submission is based on the TAX 324 phase III study showing significantly improved overall survival in patients treated with the Taxotere combination vs cisplatin/fluorouracil alone.

Recent Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
head and neck cancer
Related Content